Compare Recursion Pharmaceuticals Inc (RXRX) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Tesla, Inc. — how do they compare? Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.31B), while Tesla, Inc. trades at $380.11 (market cap $1.49T). The key difference: Tesla, Inc. is far larger — about 645× Recursion Pharmaceuticals Inc's market cap, and Tesla, Inc. is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Tesla, Inc. for 88 Days on average.
| RXRX | TSLA | |
|---|---|---|
Market Cap | $2.31B | $1.49T |
Volume | 40,478,768 | 25,496,215 |
Sector | Health | Consumer Cyclical |
52-Week High | $6.79 | $489.88 |
52-Week Low | $2.84 | $298.16 |
Typical Hold Time | 22 Days | 88 Days |
Enterprise Value | $1.83B | $1.46T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Tesla (TSLA) trades at $375.03, down 1.48% with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss ($0.33 actual vs $0.50 expected) following two previous beats, with revenue declining to $94.83B in 2025. Analyst sentiment remains divided with 41% buy ratings but a consensus price target of $441.36 suggesting 18% upside. Recent regulatory approval for driver-assistance software in Europe provides near-term catalyst potential.
Tesla faces execution risks amid slowing auto growth but maintains leadership in autonomous driving technology. The stock's premium valuation (P/E 349.82) requires successful expansion into robotics and AI to justify current levels. Near-term pressure from delivery misses contrasts with long-term potential in energy and autonomy markets, creating a high-risk, high-reward investment profile.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
